PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk - Rehues, Pere; Girona, Josefa; Guardiola, Montse; Plana, Núria; Scicali, Roberto; Piro, Salvatore; Muñiz-Grijalvo, Ovidio; Díaz-Díaz, José Luis; Recasens, Lluís; Pinyol, Marta; Rosales, Roser; Esteban, Yaiza; et al. (International journal of molecular sciences, 2023)
Keywords: Anti-Inflammatory Agents; Apolipoprotein C-III; Apolipoproteins; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases - etiology; Cholesterol; Cholesterol, LDL; Confounding (Statistics); Cytokines; Glycoproteins; Heart Disease Risk Factors; High density lipoprotein; Humans; Hypertension; Inflammation; Inflammation - complications; Inflammation - drug therapy; Lipoproteins; Low density lipoprotein; Magnetic Resonance Spectroscopy - adverse effects; Monoclonal antibodies; NMR; Nuclear magnetic resonance; Observational studies; PCSK9 Inhibitors; Plasma; Proprotein Convertase 9 - metabolism; Proton Magnetic Resonance Spectroscopy; Risk Factors; Statins; Triglycerides; PCSK9; alirocumab; glycoproteins; apolipoprotein C-III; LDL; inflammation